Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “OVARY”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 199 records · Page 11Linked to original sources
PubMed1980

Specific binding of prolactin to the mammary gland and lactose synthesis in pregnant rats after removal of ovaries or ovaries and adrenals.

Ovariectomy performed at mid pregnancy increased the specific binding of 125I-prolactin to the mammary gland (expressed as cpm/mg DNA) in rats 40 hr after the operation. When adrenals were removed simultaneously at the time of ovariectomy, no increase in the specific binding was observed. An appreciable amount of lactose was found in all mammary glands of ovariectomized-adrenalectomized animals, though the content was less than half of that of the ovariectomized animals. The plasma level of prolactin in ovariectomized and ovariectomized-adrenalectomized rats was slightly higher than that in sham operated control rats, though the differences were not statistically significant. These results seem to indicate that the adrenal gland is necessary for the induction of the site of specific binding of prolactin in the mammary gland of the rat and that an increase in the circulating levels of prolactin does not seem to play an essential role in the initiation of milk synthesis in this species.

Adrenal Glands↗
PubMed1991

P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.

P-glycoprotein (P-gp) expression and DNA topoisomerase (Topo) II are important variables in multidrug resistant tumor cell lines. The aim of this study was to evaluate P-gp expression and Topo I and II activity in benign and malignant epithelial ovarian tumors. P-gp expression was analyzed immunohistochemically in cryostat sections of fresh tumor specimens. In the same specimens Topo I and II activity were measured by, respectively, relaxation of supercoiled plasmid pBR322 DNA and decatenation of kinetoplast DNA. P-gp expression (range, 5-100% positive staining cells) was found in 3 of 6 cystadenomas, 0 of 2 borderline tumors, 15 of 21 untreated ovarian cancers, and 8 of 13 platinum/cyclophosphamide treated ovarian cancers. Median Topo I and II activity were elevated in malignant ovarian tumors compared to benign and borderline tumors. No difference was found between median Topo I activity in untreated ovarian cancer and platinum/cyclophosphamide treated ovarian cancer. High Topo II activity (greater than or equal to 8 x 10(2) units/mg protein) was more frequent in untreated compared to platinum/cyclophosphamide treated samples. Respectively, 8- and 16-fold differences in Topo I and II activity were found in the malignant tumors. Topo II activity in malignant tumors correlated with Topo I activity (r = 0.36, P less than 0.05) and the tumor volume index (r = 0.35, P less than 0.05). However, this last weak correlation cannot explain the 16-fold differences in Topo II activity in malignant tumors. Mitotic index and P-gp expression did not correlate with Topo I or II activity. A large variability in P-gp expression and Topo I and II activity was observed in patients with ovarian cancer.

ATP Binding Cassette Transporter, Subfamily B, Mem↗